Integra LifeSciences Holdings Future Growth
Future criteria checks 3/6
Integra LifeSciences Holdings is forecasted to grow earnings and revenue by 24.9% and 4.2% per annum respectively. EPS is expected to grow by 21.1%. Return on equity is forecast to be 15.6% in 3 years.
Key information
24.9%
Earnings growth rate
21.1%
EPS growth rate
| Medical Equipment earnings growth | 21.0% |
| Revenue growth rate | 4.2% |
| Future return on equity | 15.6% |
| Analyst coverage |
Good |
| Last updated | 24 Aug 2023 |
Recent future growth updates
Recent updates
Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 38% Discount?
Aug 15
Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Hit The Brakes
Jul 03
Is There Now An Opportunity In Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
Jun 19
Estimating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)
May 05
These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Reasonably Well
Apr 07
Integra LifeSciences Holdings (NASDAQ:IART) Is Experiencing Growth In Returns On Capital
Mar 26
At US$52.61, Is It Time To Put Integra LifeSciences Holdings Corporation (NASDAQ:IART) On Your Watch List?
Mar 14
Does Integra LifeSciences Holdings (NASDAQ:IART) Deserve A Spot On Your Watchlist?
Feb 27
Calculating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)
Feb 02
We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt
Jan 05
Here’s What To Make Of Integra LifeSciences Holdings’ (NASDAQ:IART) Decelerating Rates Of Return
Dec 21
When Should You Buy Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
Dec 08
Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 42% Discount?
Oct 19
We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt
Oct 05
Integra LifeSciences: Wide Dislocation In Fundamentals Vs. Market Value
Sep 13
Is It Time To Consider Buying Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
Sep 06
FDA labels recall of intracranial pressure monitors by Integra as most serious
Aug 31
Integra Lifesciences voluntarily recalls pressure monitors, lowers revenue, profit guidance
Aug 24
Returns At Integra LifeSciences Holdings (NASDAQ:IART) Appear To Be Weighed Down
Aug 23
Integra LifeSciences founder/former CEO dies
Aug 16
Integra LifeSciences Holdings GAAP EPS of $0.54 beats by $0.09, revenue of $398M beats by $2.62M
Jul 27
Is There An Opportunity With Integra LifeSciences Holdings Corporation’s (NASDAQ:IART) 47% Undervaluation?
Jul 20
These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Reasonably Well
Jul 07
Is It Time To Consider Buying Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
May 24
Integra LifeSciences Holdings (NASDAQ:IART) Has Some Way To Go To Become A Multi-Bagger
May 09
Is There An Opportunity With Integra LifeSciences Holdings Corporation’s (NASDAQ:IART) 32% Undervaluation?
Apr 11
These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Reasonably Well
Mar 29
Should You Be Adding Integra LifeSciences Holdings (NASDAQ:IART) To Your Watchlist Today?
Feb 28
Integra LifeSciences: Time To Show Signs Of Life Again
Feb 02
Should You Think About Buying Integra LifeSciences Holdings Corporation (NASDAQ:IART) Now?
Feb 02
An Intrinsic Calculation For Integra LifeSciences Holdings Corporation (NASDAQ:IART) Suggests It’s 21% Undervalued
Jan 01
These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Reasonably Well
Dec 19
I Ran A Stock Scan For Earnings Growth And Integra LifeSciences Holdings (NASDAQ:IART) Passed With Ease
Nov 23
What Does Integra LifeSciences Holdings Corporation’s (NASDAQ:IART) Share Price Indicate?
Nov 04
Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 30% Discount?
Sep 28
Is Integra LifeSciences Holdings (NASDAQ:IART) A Risky Investment?
Sep 07
Integra LifeSciences Seeing Good Core Growth, But Inner Turbulence Is A Concern
Aug 14
Should You Think About Buying Integra LifeSciences Holdings Corporation (NASDAQ:IART) Now?
Jul 24
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
| 12/31/2025 | 1,713 | 228 | 291 | 312 | 7 |
| 12/31/2024 | 1,629 | 176 | 269 | 290 | 12 |
| 12/31/2023 | 1,555 | 119 | 232 | 247 | 12 |
| 6/30/2023 | 1,545 | 131 | 155 | 208 | N/A |
| 3/31/2023 | 1,562 | 172 | 200 | 246 | N/A |
| 12/31/2022 | 1,558 | 181 | 217 | 264 | N/A |
| 9/30/2022 | 1,565 | 173 | 188 | 248 | N/A |
| 6/30/2022 | 1,567 | 166 | 205 | 263 | N/A |
| 3/31/2022 | 1,559 | 157 | 232 | 288 | N/A |
| 12/31/2021 | 1,542 | 169 | 264 | 312 | N/A |
| 9/30/2021 | 1,526 | 216 | 274 | 323 | N/A |
| 6/30/2021 | 1,509 | 206 | 262 | 310 | N/A |
| 3/31/2021 | 1,378 | 170 | 203 | 252 | N/A |
| 12/31/2020 | 1,372 | 134 | 140 | 204 | N/A |
| 9/30/2020 | 1,378 | 56 | 155 | 213 | N/A |
| 6/30/2020 | 1,387 | -3 | 78 | 207 | N/A |
| 3/31/2020 | 1,512 | 27 | 83 | 223 | N/A |
| 12/31/2019 | 1,518 | 50 | 97 | 231 | N/A |
| 9/30/2019 | 1,506 | 60 | 47 | 185 | N/A |
| 6/30/2019 | 1,493 | 101 | 124 | 200 | N/A |
| 3/31/2019 | 1,475 | 83 | 109 | 188 | N/A |
| 12/31/2018 | 1,472 | 61 | 122 | 200 | N/A |
| 9/30/2018 | 1,458 | 80 | 103 | 169 | N/A |
| 6/30/2018 | 1,371 | 70 | 78 | 135 | N/A |
| 3/31/2018 | 1,287 | 69 | 77 | 127 | N/A |
| 12/31/2017 | 1,188 | 65 | 71 | 115 | N/A |
| 9/30/2017 | 1,075 | 49 | 59 | 110 | N/A |
| 6/30/2017 | 1,047 | 66 | 61 | 111 | N/A |
| 3/31/2017 | 1,014 | 68 | N/A | 120 | N/A |
| 12/31/2016 | 992 | 75 | N/A | 116 | N/A |
| 9/30/2016 | 985 | 61 | N/A | 136 | N/A |
| 6/30/2016 | 958 | 9 | N/A | 108 | N/A |
| 3/31/2016 | 919 | 9 | N/A | 98 | N/A |
| 12/31/2015 | 883 | 7 | N/A | 105 | N/A |
| 9/30/2015 | 854 | 12 | N/A | 100 | N/A |
| 6/30/2015 | 827 | 53 | N/A | 111 | N/A |
| 3/31/2015 | 782 | 46 | N/A | 100 | N/A |
| 12/31/2014 | 797 | 36 | N/A | 84 | N/A |
| 9/30/2014 | 798 | 30 | N/A | 70 | N/A |
| 6/30/2014 | 814 | -10 | N/A | 70 | N/A |
| 3/31/2014 | 855 | -13 | N/A | 57 | N/A |
| 12/31/2013 | 697 | 22 | N/A | 53 | N/A |
| 9/30/2013 | 830 | -22 | N/A | 38 | N/A |
| 6/30/2013 | 827 | 21 | N/A | 35 | N/A |
| 3/31/2013 | 831 | 28 | N/A | 35 | N/A |
| 12/31/2012 | 831 | 41 | N/A | 59 | N/A |
| 9/30/2012 | 820 | 33 | N/A | 97 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IART’s forecast earnings growth (24.9% per year) is above the savings rate (2.2%).
Earnings vs Market: IART’s earnings (24.9% per year) are forecast to grow faster than the US market (15.5% per year).
High Growth Earnings: IART’s earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: IART’s revenue (4.2% per year) is forecast to grow slower than the US market (7.8% per year).
High Growth Revenue: IART’s revenue (4.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IART’s Return on Equity is forecast to be low in 3 years time (15.6%).